@article{oai:niigata-u.repo.nii.ac.jp:00023494,
 author = {渡辺, 裕 and 村山, 久夫},
 issue = {5},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {May},
 note = {The cure rate for endoscopic therapy was determined in 61 patients with a gastroduodenal ulcer who received Ranitidine at a dose of 150 mg twice daily, in the morning and evening. The ulcer patients were classified into initial-, recurrent-and intractable-ulcer groups, and the cumulative cure rate was compared among the three types of ulcers. The cure rate was 93% for the initial ulcer, 78% for recurrent and 50% for intractable. Uncured ulcers accounted for about 10% of the patients, and the rate of uncured ulcers was particularly high among duodenal ulcer patients. The patients' background factors such as smoking or nonsmoking, seasonal variation, and blood type were also compared among the three groups of patients. Specific endoscopic findings which were studied after use of an H_2-blocker were characterized by an elevation of the mucous membrane around the ulcer. The effects of H_2-blocker dosage reduction and discontinuation on gastroduodenal were determined. Given the fact that all patients relapsed after discontinuation of the H_2-blocker, ulcers seem to indicate maintenance H_2-blocker therapy, and smoking patients, among others, appear to be in need of lifetime therapy. When using an H_2-blocker, its indication should be clearly determined, and therapy should be instituted in due consideration of an ulcer as a psychosomatic disorder.},
 pages = {255--261},
 title = {3) H_2-受容体拮抗薬による治療 : ラニチジンを中心に(シンポジウム 食道・胃・十二指腸潰瘍の薬物療法, 第416回新潟医学会)},
 volume = {102},
 year = {1988}
}